Understanding Your Child's Juvenile Paget Disease Diagnosis
At a Glance
Juvenile Paget disease is an ultra-rare inherited condition that makes a child’s bones remodel too quickly. Bones may become enlarged but weak, leading to bowing, fractures, pain, or short stature; early specialist care may improve mobility and symptoms.
Receiving a diagnosis of Juvenile Paget Disease (JPD) for your child is often an overwhelming experience that begins with more questions than answers. Because this condition is ultra-rare—meaning it affects only a very small number of children worldwide—it is likely that your local pediatrician or family doctor has never encountered it before [1][2].
This page is designed to help you orient yourself to this diagnosis, understand the biology of what is happening in your child’s body, and validate the complex emotions that come with caring for a child with a rare genetic condition.
Understanding the “Rapid Remodeling”
In a healthy body, bone is constantly being broken down and rebuilt in a balanced process. In a child with JPD, this balance is lost. The most common form of the disease is an autosomal recessive inherited disorder, meaning a child inherits a specific genetic change from both parents [2][3].
Most cases are caused by a mutation in the TNFRSF11B gene, which is responsible for producing a protein called osteoprotegerin (OPG) [2]. Think of OPG as a “brake” on the cells that break down bone. Without enough of this protein, the “brake” fails, and the body begins to break down and rebuild bone at an abnormally rapid rate [3][4]. This high-turnover remodeling results in bone that is often larger than normal but much weaker, leading to the characteristic features of the condition [2][1].
Navigating the Diagnosis
Because JPD is so rare, the journey to a diagnosis (sometimes called a “diagnostic odyssey”) can be exhausting and filled with uncertainty [5]. You may have first noticed bowing of the legs, a change in the shape of your child’s skull, or a fracture that seemed to happen too easily [2][1].
One of the primary markers doctors look for is a severely elevated level of alkaline phosphatase (ALP), an enzyme in the blood that signals active bone formation [6][7]. While ALP is naturally higher in growing children, the levels in JPD are typically many times higher than normal, and must be interpreted in the context of age and puberty [6].
Common Fears and Realities
It is completely natural to experience caregiver stress or intense worry about your child’s future [5]. Many parents fear that their child will face constant pain or be unable to walk.
The reality of JPD is that the course of the disease varies significantly from one child to another based on their specific genetic makeup, though a specific variant may not reliably predict an individual child’s course [1][8].
- Skeletal Impacts: Without treatment, the rapid bone turnover can lead to progressive bowing of the long bones, frequent fractures, and short stature [2][1].
- Beyond the Bones: Because the genetic change affects the whole body, some children may experience “extra-skeletal” symptoms, such as sensorineural hearing loss (hearing loss caused by changes in the inner ear or nerves) or issues with vision and heart health, though these are not guaranteed [1][8][9].
- The Power of Early Intervention: While the condition is serious, published cases show that children who receive early, specialized treatment have sometimes experienced significant improvements in bone pain and mobility [10][11]. While favorable outcomes are possible, they are not guaranteed, and treatment responses vary [11].
The Emotional Journey
Caring for a child with an ultra-rare skeletal disorder is an emotional marathon. Research among caregivers in the broader rare-bone-disease community has found high levels of caregiver stress [12].
You may feel:
- Isolation: The feeling that no one—not even your doctors—quite understands what you are going through [5][13].
- Helplessness: Watching your child experience pain or physical changes can feel overwhelming [14].
- Uncertainty: Because the disease is so rare, there is no “standard” roadmap, and treatment is often individualized [15][10].
Finding a community of other “rare” parents, even if their children have different bone conditions, can provide vital emotional support and help you navigate the complexities of the healthcare system [5][16]. You are the expert on your child, and your observations are the most valuable tool your medical team has.
Common questions in this guide
What causes juvenile Paget disease in a child?
What does a very high alkaline phosphatase level mean in juvenile Paget disease?
What symptoms can juvenile Paget disease cause?
Can early treatment improve a child's juvenile Paget disease?
Why should a child with juvenile Paget disease see a bone specialist?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
About the condition
Could you explain what high-turnover remodeling means for my child's bones?
About testing
Would my child's alkaline phosphatase level be checked, and how is it read for age?
Effects beyond bones
Could this condition affect my child's hearing, vision, or heart, and how would we know?
Get notified when new evidence is published on Juvenile Paget disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Juvenile Paget disease.
Polyzos SA, Cundy T, Mantzoros CS
Metabolism: clinical and experimental 2018; (80()):15-26 doi:10.1016/j.metabol.2017.10.007.
PMID: 29080812 - 2
Juvenile Paget's Disease From Heterozygous Mutation of SP7 Encoding Osterix (Specificity Protein 7, Transcription Factor SP7).
Whyte MP, Campeau PM, McAlister WH, et al.
Bone 2020; (137()):115364 doi:10.1016/j.bone.2020.115364.
PMID: 32298837 - 3
Genetic disorders associated with the RANKL/OPG/RANK pathway.
Xue JY, Ikegawa S, Guo L
Journal of bone and mineral metabolism 2021; (39(1)):45-53 doi:10.1007/s00774-020-01148-4.
PMID: 32940787 - 4
Auricular ossification: A newly recognized feature of osteoprotegerin-deficiency juvenile Paget disease.
Gottesman GS, Madson KL, McAlister WH, et al.
American journal of medical genetics. Part A 2016; (170A(4)):978-85 doi:10.1002/ajmg.a.37536.
PMID: 26762549 - 5
Ultra-rare ultra-care: Assessing the impact of caring for children with ultra rare diseases.
Domaradzki J, Walkowiak D
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2024; (48()):78-84 doi:10.1016/j.ejpn.2023.12.003.
PMID: 38071849 - 6
Alkaline phosphatase in paediatric practice: a practical approach with a proposed diagnostic algorithm.
Parys J, Nowicki JK, Jakubowska-Pietkiewicz E
Journal of pediatric endocrinology & metabolism : JPEM 2026; doi:10.1515/jpem-2026-0400.
PMID: 42867915 - 7
The first neonatal case of Juvenile Paget disease with homozygous deletion in the TNFRSF11B gene.
Yarci E, Turen B, Ozturk Yarci D, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2026; (39(10)):1060-1065 doi:10.1515/jpem-2026-0056.
PMID: 42112796 - 8
Loss of Functional Osteoprotegerin: More Than a Skeletal Problem.
Grasemann C, Unger N, Hövel M, et al.
The Journal of clinical endocrinology and metabolism 2017; (102(1)):210-219 doi:10.1210/jc.2016-2905.
PMID: 27809640 - 9
Juvenile Paget's disease with compound heterozygous mutations in TNFRSF11B presenting with recurrent clavicular fractures and a mild skeletal phenotype.
Naot D, Wilson LC, Allgrove J, et al.
Bone 2020; (130()):115098 doi:10.1016/j.bone.2019.115098.
PMID: 31655221 - 10
Clinical course in two children with Juvenile Paget's disease during long-term treatment with intravenous bisphosphonates.
Höppner J, Steff K, Misof BM, et al.
Bone reports 2021; (14()):100762 doi:10.1016/j.bonr.2021.100762.
PMID: 33850973 - 11
Juvenile Paget's Disease: Report of a successful treatment throughout the complete growth of a patient with a missense TNFRSF11B mutation.
Prata AR, Saraiva J, Salgado M, Estanqueiro P
Joint bone spine 2021; (88(6)):105243 doi:10.1016/j.jbspin.2021.105243.
PMID: 34166796 - 12
Prevalence of depression and anxiety, and their relationship to social support among patients and family caregivers of rare bone diseases.
Lai X, Jiang Y, Sun Y, et al.
Orphanet journal of rare diseases 2023; (18(1)):18 doi:10.1186/s13023-022-02611-3.
PMID: 36703212 - 13
Improving care pathways for people living with rare bone diseases (RBDs): outcomes from the first RBD Summit.
Chandran M, Alves I, Carpenter T, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2023; (34(8)):1301-1310 doi:10.1007/s00198-023-06791-x.
PMID: 37294334 - 14
"Why them, why me, why us?" The experiences of parents of children with lysosomal acid lipase deficiency: an interpretative phenomenological analysis study.
Hassall S, Smith DM, Rust S, et al.
Orphanet journal of rare diseases 2022; (17(1)):193 doi:10.1186/s13023-022-02335-4.
PMID: 35550173 - 15
Osteogenesis imperfecta and the family: A qualitative analysis of the experiences of family and caregivers.
Colombo GM, Wiese AD, Mercado AE, et al.
Families, systems & health : the journal of collaborative family healthcare 2025; (43(3)):482-499 doi:10.1037/fsh0001004.
PMID: 40638332 - 16
Facebook as a Lifeboat: An Interview Study Exploring the Role of Facebook in Supporting Parents of Children with Rare Diseases.
Victor B, Yilmaz NG, Hoving C, et al.
Journal of health communication 2026; 1-13 doi:10.1080/10810730.2026.2723703.
PMID: 42687858
This page explains juvenile Paget disease for informational purposes only and does not constitute medical advice. Your child's pediatric bone specialist and medical team can interpret laboratory and genetic results and recommend care for your child.